Bendayan Reina, Lee Gloria, Bendayan Moise
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Microsc Res Tech. 2002 Jun 1;57(5):365-80. doi: 10.1002/jemt.10090.
Until recently, the blood-brain barrier was viewed as a static lipid membrane barrier. Physical attributes of the cerebral endothelial cells such as the presence of tight junctions, paucity of vesicles or caveolae, and high electrical resistance were believed to be the primary components that provide the membrane selectivity of the blood-brain barrier to a variety of circulating compounds from the periphery. However, results from molecular biology, immunocytochemistry, biochemistry, and transport studies show that the cerebral endothelial cells possess an asymmetrical array of metabolic enzymes (i.e., alkaline phosphatase, cytochrome P450 enzymes, glutathione transferases) and energy-dependent efflux transport proteins (i.e., P-glycoprotein and Multidrug-resistance proteins) that are instrumental to the barrier function. P-glycoprotein, a membrane-associated, energy-dependent, efflux transporter, is expressed in brain parenchyma (i.e., astrocytes and microglia) as well as in blood-brain and blood-cerebrospinal fluid barriers. Its function along the blood-brain barrier is believed to prevent the accumulation of potentially harmful compounds in the brain by actively removing them from the brain into the peripheral circulation. This is a brief review on the expression and activity of P-glycoprotein at the blood-brain barrier, which reports on the localization of the protein in rat brain capillaries in situ as well as in a well-characterized in vitro model of the blood-brain barrier, an immortalized rat brain endothelial cell line, the RBE4. Immunocytochemical analysis employing various P-glycoprotein monoclonal antibodies, demonstrated the presence of the protein along the plasma membrane, in plasmalemmal vesicles and nuclear envelope of rat cerebral endothelial cells, both in situ and in vitro. Western blot analysis revealed a single band with a molecular weight of 170-180 kDa, a size previously reported for P-glycoprotein, in RBE4 cells. In addition, results from functional studies show that the accumulation of the P-glycoprotein substrate digoxin by RBE4 monolayer cells is significantly enhanced in the presence of standard P-glycoprotein inhibitors (verapamil, cyclosporin A, PSC 833), protease inhibitors (saquinavir, ritonavir, indinavir), and the metabolic inhibitor, sodium azide. These results demonstrate the functional expression of P-glycoprotein in the immortalized rat brain endothelial cell line, RBE4. Novel in situ and in vitro intracellular locations of P-glycoprotein in cerebral endothelial cells have been identified suggesting that this transporter may play a significant role in the subcellular distribution of substrates in the brain.
直到最近,血脑屏障还被视为一种静态的脂质膜屏障。脑内皮细胞的物理特性,如紧密连接的存在、囊泡或小窝的稀少以及高电阻,被认为是赋予血脑屏障对来自外周的各种循环化合物具有膜选择性的主要成分。然而,分子生物学、免疫细胞化学、生物化学和转运研究的结果表明,脑内皮细胞拥有不对称排列的代谢酶(即碱性磷酸酶、细胞色素P450酶、谷胱甘肽转移酶)和能量依赖性外排转运蛋白(即P-糖蛋白和多药耐药蛋白),这些对屏障功能至关重要。P-糖蛋白是一种与膜相关的、能量依赖性的外排转运体,在脑实质(即星形胶质细胞和小胶质细胞)以及血脑屏障和血脑脊液屏障中均有表达。其在血脑屏障中的功能被认为是通过将潜在有害化合物从脑内主动转运到外周循环中,从而防止它们在脑内蓄积。这是一篇关于血脑屏障处P-糖蛋白表达和活性的简要综述,报告了该蛋白在大鼠脑毛细血管原位以及在一个特征明确的血脑屏障体外模型(一种永生化大鼠脑内皮细胞系RBE4)中的定位。采用各种P-糖蛋白单克隆抗体的免疫细胞化学分析表明,该蛋白在大鼠脑内皮细胞的质膜、质膜囊泡和核膜上均有存在,无论是在原位还是在体外。蛋白质印迹分析显示,在RBE4细胞中出现了一条分子量为170 - 180 kDa的条带,这是先前报道的P-糖蛋白的大小。此外,功能研究结果表明,在标准P-糖蛋白抑制剂(维拉帕米、环孢素A、PSC 833)、蛋白酶抑制剂(沙奎那韦、利托那韦、茚地那韦)和代谢抑制剂叠氮化钠存在的情况下,RBE4单层细胞对P-糖蛋白底物地高辛的蓄积显著增强。这些结果证明了P-糖蛋白在永生化大鼠脑内皮细胞系RBE4中的功能性表达。已确定了脑内皮细胞中P-糖蛋白新的原位和体外细胞内定位,这表明该转运体可能在脑中底物的亚细胞分布中发挥重要作用。